FastWave Medical, a leading medical device company, has recently been granted its fifth utility patent by the United States Patent and Trademark Office (USPTO), marking a significant achievement in the expansion of its intellectual property portfolio.
The company, known for its innovative intravascular lithotripsy (IVL) technology, has been dedicated to addressing challenges in treating calcific disease, a common issue in managing vascular blockages. Dr. Peter Schneider, a Professor of Surgery at the University of California San Francisco, commended FastWave’s efforts in developing IVL systems that offer substantial improvements in treating calcific disease.
The newly granted patent underscores the advanced design of FastWave’s next-generation IVL platform, specifically tailored to tackle the complexities of treating calcified arteries in patients with occlusive vascular disease. This condition affects millions worldwide and is a major contributor to cardiovascular morbidity and mortality.
FastWave aims to bridge gaps in current IVL solutions by enhancing ease of use, patient safety, and reducing procedural complications through its cutting-edge lithotripsy platforms.
Scott Nelson, the co-founder and CEO of FastWave Medical, expressed enthusiasm over the company’s progress and the value of their expanding IP portfolio. He highlighted the collaboration with medical advisors in creating practical clinical solutions for healthcare providers and their patients.
FastWave Medical Inc. is dedicated to developing advanced IVL systems for calcific artery disease, with a focus on improving procedural efficiency and elevating the overall patient care experience. The company’s commitment to innovation and collaboration underscores its mission to redefine the sector with next-generation IVL technologies.
For more information about FastWave Medical, visit their official website at FastWave Medical.
If you have any media inquiries, you can reach out to FastWave Medical at (833) 888-9283 or via email at media@fastwaveme.
